Quality is the foundation of patient safety. We uphold a rigorous quality culture and maintain internal control standards aligned with Chinese, US, European, Japanese pharmacopoeias anc ICH guidelines. Our quality management system complies with China GMP, EU GMP. US CGMP and lCH requirements.

We manage the entire product R&D lifecycle-from R&D,raw material procurement and manufacturing to release and post-market monitoring-with strict standards and full traceability at every stage.

Our commitment to quality goes beyond regulatory compliance. lt reflects our responsibility to patient health and safety.We pursue excellence through craftsmanship, build trust through integrity, and drive a sustainable future through quality innovation

Driven by innovation,we leverage an experienced R&D team, advanced technology platforms, and industry-leading instruments to focus on key therapeutic areas such as psychiatry, antivirals, and oncology, continuously pursuing technological breakthroughs and process optimization.

Through a comprehensive R&D pipeline spanning formulation development, process scale-up, and quality evaluation, we achieve efficient translation of innovation into tangible outcomes.

To date, we hold 122 approved drug products, including 3 exclusive approvals among these, 73 products are included in National Reimbursement Drug List (NRDL)and 51 products are on National Essential Medicines List (NEML), forming a broadly covered, well-structured,and highly competitive product portfolio.